目的探讨首发精神分裂症缺陷型与非缺陷型患者视觉图形记忆的差异。方法纳入199例首发未治疗精神分裂症患者及148名正常对照。采用缺陷型精神分裂症诊断量表中文版(Schedule for the Deficit Syn drome,SDS)将患者分为缺陷型(51例)和非...目的探讨首发精神分裂症缺陷型与非缺陷型患者视觉图形记忆的差异。方法纳入199例首发未治疗精神分裂症患者及148名正常对照。采用缺陷型精神分裂症诊断量表中文版(Schedule for the Deficit Syn drome,SDS)将患者分为缺陷型(51例)和非缺陷型(148例)两组。使用视觉图形记忆(Pattern Recognition Memo ry,PRM)工具评定患者和对照的即刻与延迟时相图形记忆功能。用阳性与阴性症状量表(Positive and NegativeSymptom Scale,PANSS)评定两组患者的症状严重程度。结果与对照组比较,两患者组(除非缺陷型即刻时相反应时长外)所有图形记忆功能均较差(P<0.05)。两组患者间比较,即刻时相图形记忆功能差异无统计学意义([3751.00±2552.89)vs(.2999.80±1834.20),P=0.22;(86.49±15.34)vs(.87.28±16.00),P=0.96],而延迟时相缺陷型较非缺陷型反应时长更长([5086.80±7528.54)vs(.3527.40±3649.08),P<0.01],正确率更低([63.10±19.17)vs(.70.69±15.34),P<0.01]。图形记忆指标与缺陷型患者的阴性症状无相关性(P>0.05)。结论精神分裂症在疾病早期认知功能视觉图形记忆即受到损害。首发缺陷型精神分裂症图形记忆功能只有在延迟时相才与非缺陷型表现出差异,记忆反应时长在即刻与延迟时相始终延长。提示这是一类具有特征性的认知功能缺损特点的精神分裂症亚型。展开更多
Background The impairment of social function is widespread in the patients with chronic schizophrenia, which seriously affects family, life and work conditions.Aims The main purpose of this study was to investigate th...Background The impairment of social function is widespread in the patients with chronic schizophrenia, which seriously affects family, life and work conditions.Aims The main purpose of this study was to investigate the efficacy of paliperidone in the treatment of social function in chronic schizophrenia.Methods A total of 81 patients who met the standard criteria for schizophrenia and long-term hospitalised inpatients were randomly divided into the treatment group and normal control group following a 1-year prospective follow-up study. The reatment group(41 cases) used paliperidone extended-release tablets for reducing dosage, as appropriate, based on the original treatment strategy; and the control group(40 cases) used the former drugs. All patients were assessed using the Positive and Negative Symptom Scales(PANSS), and the Treatment Emergent Symptom Scale(TESS) was used to assess adverse drug reactions. The Hospitalised Psychiatric Patients' Social Functions Rating Scale(SSPI) was used to assess social function of participants before and after 8 weeks, 6 months and 1 year of treatment.Results At baseline there were no significant differences between the two groups in age, duration of illness, educational background and dosage of antipsychotic drugs(converted into chlorpromazine equivalency). There was statistically significant difference in PANSS positive symptoms by interaction effect(Fgroup×time=18.24, df=3237, p<0.001) and time effect(Ftime=21.66, df=3, p<0.01) and the difference in PANSS positive symptoms by grouping effect(Fgroup=0.68, df=1, p=0.41) was not statistically significant. The difference of grouping effect of PANSS negative symptoms(Fgroup=9.93, df=1, p=0.002), time effect(Ftime=279.15, df=3, p<0.001) and interaction effect(Fgroup×time=279.15, df=3237, p<0.001) were statistically significant. There were statistically significant differences in the grouping effect(Fgroup=6.59, df=1, p=0.012), time effect(Ftime=152.97, df=3, p<0.001) and interaction effect(Fgroup×time=148.82, df=3237, p<0.001) of PANSS general pathological symptoms, the same as the total score of the PANSS, which showed large differences in grouping effect(Fgroup=7.04, df=1, p=0.001), time effect(Ftime=210.78, df=3, p<0.001) and interaction effect(Fgroup×time=205.20, df=3237, p<0.01). We found in the total SSPI score, grouping effect(Fgroup=31.70, df=1, p<0.001), time effect(Ftime=161.84, df=3, p<0.001) and interaction effect(Fgroup×time=132.74, df=3237, p<0.001) were demonstrated to be significantly different. Even though adverse reactionsoccurred 7 times in the treatment group and 44 times in the control group based on the Treatment Emergent Symptom Scale(TESS), incidence rate was significantly lower than that of the control group(χ2=18.854, p<0.001).Conclusion Paliperidone can safely and effectively improve negative symptoms and social function in patients with chronic schizophrenia.展开更多
Objective:The efficacy and occurrence of adverse reactions of prescriptions containing phlegm-resolving Chinese medicine combined with risperidone in the treatment of schizophrenia were retrospectively studied by mean...Objective:The efficacy and occurrence of adverse reactions of prescriptions containing phlegm-resolving Chinese medicine combined with risperidone in the treatment of schizophrenia were retrospectively studied by means of meta-analysis.Methods:A variety of different Chinese and English databases were searched from January 1,2000 to May 1,2020.Review Manager 5.3 software was used to evaluate the methodological quality of the included studies.The positive and negative symptom scale(PANSS)was used as the evaluation standard to analyze the total scores,positive scores,negative scores and general psychopathological scores,clinical efficacy and safety of prescriptions containing phlegmresolving Chinese medicine combined with risperidone of schizophrenia.The heterogeneity test and sensitivity analysis were also carried out by Review Manager 5.3,and the potential publication bias was analyzed by"funnel plot".Results:A total of 1515 patients were included in 15 studies.Compared with control group of risperidone alone,the total PANSS scale score,positive symptom score,negative symptom score and general psychopathological score of the treatment group of phlegm-resolving Chinese medicine combined with risperidone were all lower than those of the control group(P=0.01,MD=-6.35,95%CI[-11.29,-1.40]),(P=0.04,MD=-1.42,95%CI[-2.74,-0.09]),(P<0.01,MD=-2.16,95%CI[-3.41,-0.91]),and(P<0.01,MD=-3.80,95%CI[-6.37,-1.24]),the clinical efficacy of phlegm-resolving Chinese medicine combined with risperidone treatment group on schizophrenia was better than that of the control group[P<0.01,RR=1.09,95%CI(1.05-1.13)].The incidence of adverse reactions was reduced(P=0.02,RR=0.56,95%CI[0.34-0.93]).Conclusion:The combination of prescriptions containing phlegm-resolving Chinese medicine and risperidone can effectively improve the efficacy of patients with schizophrenia and reduce the occurrence of adverse drug reactions compared with risperidone alone.展开更多
文摘目的探讨首发精神分裂症缺陷型与非缺陷型患者视觉图形记忆的差异。方法纳入199例首发未治疗精神分裂症患者及148名正常对照。采用缺陷型精神分裂症诊断量表中文版(Schedule for the Deficit Syn drome,SDS)将患者分为缺陷型(51例)和非缺陷型(148例)两组。使用视觉图形记忆(Pattern Recognition Memo ry,PRM)工具评定患者和对照的即刻与延迟时相图形记忆功能。用阳性与阴性症状量表(Positive and NegativeSymptom Scale,PANSS)评定两组患者的症状严重程度。结果与对照组比较,两患者组(除非缺陷型即刻时相反应时长外)所有图形记忆功能均较差(P<0.05)。两组患者间比较,即刻时相图形记忆功能差异无统计学意义([3751.00±2552.89)vs(.2999.80±1834.20),P=0.22;(86.49±15.34)vs(.87.28±16.00),P=0.96],而延迟时相缺陷型较非缺陷型反应时长更长([5086.80±7528.54)vs(.3527.40±3649.08),P<0.01],正确率更低([63.10±19.17)vs(.70.69±15.34),P<0.01]。图形记忆指标与缺陷型患者的阴性症状无相关性(P>0.05)。结论精神分裂症在疾病早期认知功能视觉图形记忆即受到损害。首发缺陷型精神分裂症图形记忆功能只有在延迟时相才与非缺陷型表现出差异,记忆反应时长在即刻与延迟时相始终延长。提示这是一类具有特征性的认知功能缺损特点的精神分裂症亚型。
基金supported in part by the National Science Fund of China(81771450,81471358)Shanghai Health Bureau scientific research grant(201540029)Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant(20152530)
文摘Background The impairment of social function is widespread in the patients with chronic schizophrenia, which seriously affects family, life and work conditions.Aims The main purpose of this study was to investigate the efficacy of paliperidone in the treatment of social function in chronic schizophrenia.Methods A total of 81 patients who met the standard criteria for schizophrenia and long-term hospitalised inpatients were randomly divided into the treatment group and normal control group following a 1-year prospective follow-up study. The reatment group(41 cases) used paliperidone extended-release tablets for reducing dosage, as appropriate, based on the original treatment strategy; and the control group(40 cases) used the former drugs. All patients were assessed using the Positive and Negative Symptom Scales(PANSS), and the Treatment Emergent Symptom Scale(TESS) was used to assess adverse drug reactions. The Hospitalised Psychiatric Patients' Social Functions Rating Scale(SSPI) was used to assess social function of participants before and after 8 weeks, 6 months and 1 year of treatment.Results At baseline there were no significant differences between the two groups in age, duration of illness, educational background and dosage of antipsychotic drugs(converted into chlorpromazine equivalency). There was statistically significant difference in PANSS positive symptoms by interaction effect(Fgroup×time=18.24, df=3237, p<0.001) and time effect(Ftime=21.66, df=3, p<0.01) and the difference in PANSS positive symptoms by grouping effect(Fgroup=0.68, df=1, p=0.41) was not statistically significant. The difference of grouping effect of PANSS negative symptoms(Fgroup=9.93, df=1, p=0.002), time effect(Ftime=279.15, df=3, p<0.001) and interaction effect(Fgroup×time=279.15, df=3237, p<0.001) were statistically significant. There were statistically significant differences in the grouping effect(Fgroup=6.59, df=1, p=0.012), time effect(Ftime=152.97, df=3, p<0.001) and interaction effect(Fgroup×time=148.82, df=3237, p<0.001) of PANSS general pathological symptoms, the same as the total score of the PANSS, which showed large differences in grouping effect(Fgroup=7.04, df=1, p=0.001), time effect(Ftime=210.78, df=3, p<0.001) and interaction effect(Fgroup×time=205.20, df=3237, p<0.01). We found in the total SSPI score, grouping effect(Fgroup=31.70, df=1, p<0.001), time effect(Ftime=161.84, df=3, p<0.001) and interaction effect(Fgroup×time=132.74, df=3237, p<0.001) were demonstrated to be significantly different. Even though adverse reactionsoccurred 7 times in the treatment group and 44 times in the control group based on the Treatment Emergent Symptom Scale(TESS), incidence rate was significantly lower than that of the control group(χ2=18.854, p<0.001).Conclusion Paliperidone can safely and effectively improve negative symptoms and social function in patients with chronic schizophrenia.
基金National Natural Scicnce Foundation of China(No.81973747,81873299)。
文摘Objective:The efficacy and occurrence of adverse reactions of prescriptions containing phlegm-resolving Chinese medicine combined with risperidone in the treatment of schizophrenia were retrospectively studied by means of meta-analysis.Methods:A variety of different Chinese and English databases were searched from January 1,2000 to May 1,2020.Review Manager 5.3 software was used to evaluate the methodological quality of the included studies.The positive and negative symptom scale(PANSS)was used as the evaluation standard to analyze the total scores,positive scores,negative scores and general psychopathological scores,clinical efficacy and safety of prescriptions containing phlegmresolving Chinese medicine combined with risperidone of schizophrenia.The heterogeneity test and sensitivity analysis were also carried out by Review Manager 5.3,and the potential publication bias was analyzed by"funnel plot".Results:A total of 1515 patients were included in 15 studies.Compared with control group of risperidone alone,the total PANSS scale score,positive symptom score,negative symptom score and general psychopathological score of the treatment group of phlegm-resolving Chinese medicine combined with risperidone were all lower than those of the control group(P=0.01,MD=-6.35,95%CI[-11.29,-1.40]),(P=0.04,MD=-1.42,95%CI[-2.74,-0.09]),(P<0.01,MD=-2.16,95%CI[-3.41,-0.91]),and(P<0.01,MD=-3.80,95%CI[-6.37,-1.24]),the clinical efficacy of phlegm-resolving Chinese medicine combined with risperidone treatment group on schizophrenia was better than that of the control group[P<0.01,RR=1.09,95%CI(1.05-1.13)].The incidence of adverse reactions was reduced(P=0.02,RR=0.56,95%CI[0.34-0.93]).Conclusion:The combination of prescriptions containing phlegm-resolving Chinese medicine and risperidone can effectively improve the efficacy of patients with schizophrenia and reduce the occurrence of adverse drug reactions compared with risperidone alone.
